WRBY
Warby Parker Inc.
NYSE · Healthcare · Medical - Instruments & Supplies · US
$24.28
+4.25%Year over year
Reported trailing growth
- Revenue
- +11.0%
- EBITDA
- +125.2%
- EBIT
- +108.6%
- EPS
- +186.5%
- Free cash flow
- -58.5%
- Operating cash flow
- -18.3%
Forward estimates
Based on analyst estimates
- Revenue
- +15.1%
- EBITDA
- +123.5%
- EPS
- +570.6%
Three-year CAGR
- Revenue
- +13.4%
- EBITDA
- +102.4%
- EBIT
- +82.3%
- Net income
- +108.0%
- EPS
- +107.9%
- Free cash flow
- +144.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026